Lung cancer has a high morbidity rate worldwide and is often resistant to therapy. Oncolytic virus therapy is a developing trend for cancer treatment. Thus, we constructed an oncolytic poxvirus carrying human trail gene that expresses a membrane-binding tumor necrosis factor and associated apoptosis-inducing ligand (TRAIL, Onco pox -trail). We hypothesized that the expression of trail would increase the efficacy of the oncolytic poxvirus. The effect of the TRAIL protein depends on the death receptors on the surface of different cancer cells. The expression of death receptors in lung cancer cell lines was analyzed by western blot analysis. In vitro, the oncolytic poxvirus carrying the trail gene displayed a better cytotoxicity at the cell level in the lung cancer cell line than that carrying the Onco pox -empty. TRAIL protein mainly induced apoptosis and inhibited necrosis. In vivo, two transplanted tumor models of human A549 lung cancer cells and mouse Lewis lung cancer cells were used to verify the anti-cancer effect of the oncolytic poxvirus carrying the trail gene. TUNEL staining results of the tumor histological sections also verified the anti-cancer effect. Similarly, through systemic administration of Onco pox -trail, the oncolytic poxvirus also exhibited anti-cancer effect.
Introduction
Lung cancer has a high incidence and mortality rate worldwide [1] [2] [3] . Non-small cell lung cancers (NSCLCs) constitute a large proportion of lung cancers and are largely incurable [4] . The high incidence rate of lung cancer involves the interplay between genetic and environmental factors [5] . Currently, the commonly used chemotherapeutic drugs play a significant role in therapies for lung cancer. However, they have a number of deficiencies, such as drug resistance of tumors and low efficacy against advanced tumors [6, 7] , and thus new biotherapies are required to solve these problems.
As a biological treatment, oncolytic poxvirus has shown potential in preclinical models and in clinical trials in cancer patients [8] [9] [10] . In 2015, the Amgen Company carried out an experiment using Onco HSV -GM-CSF to treat melanoma lesions on the skin and in lymph nodes that could not be completely removed by surgery [11] [12] [13] . Onco HSV -GM-CSF caused tumor regression and increased survival in patients with metastatic disease.
Oncolytic poxvirus is a DNA virus that can reproduce in the cytoplasm and has a productive tumor suppressor effect in preclinical models and clinical experiments. Because the DNA of poxvirus cannot be integrated into the host genome [14] , its carcinogenicity is lower than that of some other oncolytic viruses. Oncolytic poxvirus can also increase the permeability of blood vessels and induce cancer cell apoptosis in tumor tissue even when the oncolytic poxvirus has been injected systemically [15] , and thus it may be appropriate for cancer-targeting therapy.
The human trail gene is a member of the TNF superfamily [16, 17] , which encodes a transmembrane protein that is widely expressed in normal and cancer cells. The TRAIL protein binds to DR4 and DR5 death receptors which contain a death domain that can transmit an apoptotic signal and induce cancer cell apoptosis [18] . In contrast, other TRAIL receptors (DcR1 and DcR2) lack a complete death domain and cannot induce cell apoptosis [19, 20] .
When TRAIL protein is combined with the DR4 and DR5 membrane surface receptors, the cell begins the process of apoptosis. During the process, the trimeric compound of the two death receptors and the TRAIL protein is combined with Fas-related protein and procaspase-8 to form the Death Inducing Signaling Complex (DISC) [21] . DISC urges procaspase-8 itself to be catalyzed into active cleaved caspase-8. After caspase-8 is activated, the apoptosis signal can be delivered in a mitochondrion-dependent or -independent manner [22] , which in turn activates the effector proteins and then leads to apoptosis.
TRAIL protein has a greater ability to induce cell apoptosis than other death ligands [23, 24] . TRAIL protein is capable of inducing apoptosis in a wide range of tumor cells, such as colon, lung, breast, kidney, brain, and skin cancers [25] [26] [27] [28] [29] [30] . The TRAIL protein can induce cell apoptosis independent of p53 and, therefore it is regarded as a promising anti-cancer molecule.
Previous studies have shown that oncolytic poxvirus may promote cell death by inducing cell apoptosis and programmed necrosis in cancer cell lines [15, 31, 32] . Receptor-interacting proteins RIP1 and RIP3 are the most important regulatory proteins in the necroptosis (Nec) signaling pathways. RIP1 is the point of intersection between cell survival and cell death, while RIP3 determines the mechanism of cell death, apoptosis, or necrosis [33] . When the apoptotic pathway is activated, RIP1 induces apoptosis but not necrosis, while the Nec pathway is activated through the RIP1 protein when the apoptotic pathway is inhibited.
A combined therapy with the trail gene and oncolytic poxvirus has been applied to colon cancer and has achieved an anti-cancer effect [34] . However, surprisingly, the sensitivity of lung cancer cells to TRAIL protein was higher than that of other cancer cells. Therefore, in the present study, lung cancer cell lines were chosen for further research.
A recombinant poxvirus that can express the TRAIL protein was constructed. When oncolytic poxvirus was infected, the expression of trail gene and subsequent apoptosis of tumor cells was measured. In addition, the apoptosis-promoting ability of the oncolytic poxvirus was verified in mice xenograft models. Our results showed that the recombinant virus that expresses TRAIL protein can be used as an effective targeted drug for lung cancer.
Materials and Methods

Cell lines
The following cell lines were used: human lung cancer cell lines A549, HCC827, and H1299; human normal lung cell line Beas-2B; mouse Lewis Supplementary Fig. S1 ). The plasmids of pCBtrail and pCB-empty were constructed and transfected into the human embryonic kidney cell line HEK293 with wild-type poxvirus. The oncolytic poxvirus genomes were extracted from HEK293 cells that had been treated with Onco 
Western blot analysis
Lung cancer cells were lysed with lysis buffer (Beyotime Biotechnology, Shanghai, China). Bradford method was used to detect the protein concentration and then polyacrylamide gel electrophoresis. The protein was transferred onto PVDF membranes and the membranes were blocked with 2% bovine serum albumin and incubated with relevant primary antibodies at 4°C for 3 h, followed by incubation with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, USA) at room temperature for 0.5 h. Western blot analysis was carried out using primary antibodies against the following: DR4 (1:500 dilution; Santa Cruz Biotechnology, Santa Cruz, USA), DR5 (1:1000 dilution; Proteintech, Rosemont, USA), TRAIL (1:1000 dilution; Cell Signaling Technology, Beverly, USA), caspase-9 (1:500 dilution; Santa Cruz Biotechnology), cleaved-caspase-9 (1:1000 dilution; Proteintech, Rosemont, USA), caspase-3 (1:500 dilution; Santa Cruz Biotechnology), cleaved-caspase-3 (1:1000 dilution; Cell Signaling Technology), PARP (1:1000 dilution; Cell Signaling Technology), cleaved-PARP (1:500 dilution; Santa Cruz Biotechnology), Bcl-2 (1:1000 dilution; Beyotime Biotechnology, Shanghai, China), Bax (1:1000 dilution; Cell Signaling Technology), TRAIL (1:1000 dilution; Cell Signaling Technology), RIP1 (1:1000 dilution; Proteintech), and RIP3 (1:1000 dilution; Proteintech). Western blot results were quantified using Image J by the densitometry.
MTT assay
MTT assay was carried out as previously described [35] . Briefly, 20 μl of MTT working solution (5 mg/ml) was added to each well of a 96-well plate and incubated at 37°C for 4 h. Then, the formazan was dissolved in 150 μl of DMSO. The absorbance was measured in a microplate reader (Thermo, Massachusetts, USA) at wavelengths of 570 and 630 nm.
Cell migration assay
A549 cells (100,000 cells/well) were planted into the upper chamber of the 24-well Transwell plates (Corning Co, Corning, USA) and culture in 200 μl F15 culture medium (Gibco, Gaithersburg, USA) without fatal bovine serum (FBS). In the lower chamber, 500 μl F15 with 2% FBS was added. The A549 cells were divided into three parts: (1) ) were, respectively, subcutaneously injected into nude mice (3-4 weeks, female) or C57BL/6 mice (6-7 weeks, female), and then mice were injected with 0.8 × 10
8 PFU of poxvirus as the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
suspended in 100 μl of PBS or 100 μl PBS alone. Mice were randomly divided into different groups and poxvirus or PBS was given by intravenous injection or intratumoral injection when the average tumor size reached 80-100 mm 3 . Tumor volumes were determined by measuring the tumor length and width: volume = (width 2 × length)/2. Mice were finally sacrificed for tissue analysis. Xenograft tumors were fixed with 4% polyoxymethylene, embedded in optimal cutting temperature compound, and sectioned for TUNEL assay.
TUNEL assay
Terminal dUTP nick-end labeling (TUNEL) assays with 4′,6-diamidino-2-phenylindole (DAPI) nuclear counterstaining were performed using an Apoptosis Detection Kit (red-fluorescence; Beyotime). TUNEL staining was performed for 60 min at 37°C and DAPI staining was performed for 30 min at room temperature. The thickness of the lung tumor frozen sections was 7 μm.
Statistical analysis
All data are shown as the mean ± standard deviation (SD). Statistical analyses were performed using the Student t-test (twotailed) and Prism GraphPad software.
Results
Construction and identification of the Onco pox -trail
To identify the oncolytic poxvirus we had constructed, we designed the corresponding PCR primers, the location of which has been stamped (Fig. 1A) . The PCR primers of tk gene-F and tk gene-R were used to identify the TRAIL gene, (Fig. 1B, Lanes 1-3) . The primers of the wild-type poxvirus-Forward (W-F) and wild-type poxvirus-Reverse (W-R) were used to identify the wild-type poxvirus (Fig. 1B, Lanes 4-6 ). The primers of pCB-F and pCB-R were used to identify the length of the trail gene (Fig. 1B, Lanes 7-9 ). The gel electrophoresis analysis showed that the oncolytic poxvirus we constructed was reasonable. A549 cells were infected with Onco pox -trail, Onco pox -empty, and wild-type poxvirus, and the expression level of the TRAIL protein was determined by western blot analysis (Fig. 1C) . The results suggested that Onco pox -trail could express the TRAIL protein in lung cancer cells.
The levels of the TRAIL receptors are different between cancer cell lines DR4 and DR5 (TNFRSF10B) receptors are important components of DISC and thus the contents of DR4 and DR5 were determined in different human cancer cell lines by western blot analysis (Fig. 2A) . The results showed that the DR4 and DR5 receptors were widely expressed in the cancer cell lines, but their contents were different. Interestingly, when we analyzed the levels of receptors in the lung cancer cell lines by western blot analysis (Fig. 2B) , we found that the contents of DR4 and DR5 in the A549 and LLC cell lines were abundant than those in other cancer cell lines, and the content of DR5 was scant in the normal lung cell line Beas-2B compared with that in the lung cancer cell lines.
Anti-tumor effect of the Onco pox -trail in lung cancer cells in vitro
In order to investigate the replication ability of the poxvirus, Onco pox -empty and Onco pox -trail (MOI = 2) were used to infect the lung cancer cell lines LLC and A549, as well as the normal lung cell line Beas-2B. The density of the poxvirus was measured every other day (Fig. 3A,B) . The results indicated that Onco (Fig. 3C-F) . In the normal lung cells, there was only a slight reduction in viability even after 72 h (Fig. 3G) . In the colony formation assay, Onco pox -trail had a better inhibitory effect on cell colony-forming than PBS or Onco pox -empty (Supplemental Fig. S2A ). These results suggested that Onco pox -trail exhibited specific cytotoxicity in lung cancer cell lines in vitro.
Onco pox -trail induces cell death in lung cancer cell lines
We next investigated whether Onco pox -trail induces cell death by apoptosis alone or a mixture of necrosis and apoptosis. Hoechst33342 fluorescent staining results indicated that the (Fig. 4A) , suggesting that the TRAIL protein could induce obvious apoptosis in A549 cells. Western blot analysis was used to detect the content of major apoptosis-related proteins in the two signaling pathways (mitochondrion-dependent and independent apoptosis). As shown in Fig. 4B , the caspase-dependent apoptosis signaling pathway was activated by oncolytic poxviruses. The levels of cleaved-caspase 3 and cleavedcaspase 9 were increased but the contents of PARP and Bcl-2 were reduced, when compared with cells treated with Onco pox -empty or PBS. Bax, a pro-apoptotic protein, was increased, and the increase was correlated with the concentration of Onco pox -trail. Under the -trail for 72 h was analyzed by MTT method. Data are shown as the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. same conditions, the levels of receptor-interacting protein RIP1 and RIP3 were measured (Fig. 4C) . It was found that in the presence of TRAIL protein, the expressions of RIP1 and RIP3 protein were significantly reduced or even disappeared, suggesting that Onco pox -trail inhibited the necrosis and induced cell apoptosis in A549 cells. Flow cytometry analysis of the A549 cells treated with Onco pox -empty, Onco pox -trail or PBS showed that the apoptosis rate due to Onco pox -trail was increased, when compared with that of the control groups (Fig. 4D) .
These results demonstrated that Onco pox -trail activated the apoptosis pathway and promoted apoptosis in lung cancer cells.
Onco pox -trail suppresses the growth of xenograft tumor in vivo
To validate the tumor-suppressing ability of Onco pox -trail on lung cancer in vivo, lung xenograft mouse models were established (Fig. 5A,B) . The results showed that the tumors treated with Onco pox -trail were significantly suppressed than those treated with Onco pox -empty or PBS. The cleaved DNA would be labeled with a fluorescein-dUTP when the cell entered apoptosis. To verify the apoptosis-inducing ability of poxvirus in the tumor, we performed immunohistofluorescence on LLC tumor histological section. The (Fig. 6A) . Furthermore, TUNEL staining of tumor histological section indicated that the number of TUNEL-positive tumor cells in the group treated with Onco pox -trail was 3.23-fold more than that in the group treated with Onco pox -empty (Fig. 6B) . Data are shown as the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
Discussion
The combination therapy of an oncolytic poxvirus expressing TRAIL protein with oxaliplatin for metastatic colorectal cancer has been shown to have anti-cancer effect [34] . In the present study, we showed the apoptotic effect of TRAIL protein in lung cancer cell lines. However, the cell viability in several cancer cell lines treated with Onco pox -empty and Onco pox -trail was not significantly different between the two poxviruses.
Several studies have shown that many cancer cell lines can tolerate the TRAIL protein by mutation of the DR4 and DR5 receptors, regulation of Bcl-2 protein, and the membrane location of DR4 and DR5 [36] [37] [38] . TRAIL protein promotes the proliferation of cancer cells that are tolerant to the TRAIL protein [23] .
In this study, Onco pox -trail was found to induce cell apoptosis in lung cancer cells, while Onco pox -empty might induce cell necrosis in lung cancer cells. In the necrosis pathway, the expression of RIP3 is related to the Nec. The occurrence of Nec is related to the formation of the RIP1/RIP3 complex. The knockout of RIP in cancer cells could completely inhibit cell necrosis [39] . Here, we came to a conclusion that necrosis was inhibited during the apoptosis induced by the TRAIL protein. Supplementary Fig. S2B ), indicating that poxvirus had no obvious effect on cell migration.
In the mice xenograft model, we found that Onco pox -trail could not inhibit the growth of the tumor completely, which may be due to the immune system, although the poxvirus had an immuneescape mechanism [40, 41] .
In the process of removing the tumor, we found that tumors treated with Onco pox -trail were very soft and that they had many purulent substances inside. After cleaning, the tumor volume was one-third of that before cleaning, but this was not found in other groups. Thus, we suggested that TRAIL protein may cause a strong immune response inside the tumor. In the TUNEL assay, the group treated with Onco pox -trail had more obvious areas of apoptosis and these apoptosis areas were close to the inflammatory region in the tumor.
The killing effect of oncolytic poxvirus in lung cancer cells were usually increased with the increased concentrations. However, although high concentration of oncolytic poxvirus could induce apoptosis of lung cancer cells, it may also induce slight toxicity in the normal lung cells. Thus, the dose of poxvirus must be carefully titrated.
In conclusion, gene therapy, as a potential cancer treatment strategy, has been widely studied [42] . In this study, we constructed an oncolytic poxvirus expressing TRAIL protein and found that it could suppress the development of lung cancer cells both in vitro 
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